Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study.

Yalcin S, Dane F, Oksuzoglu B, Ozdemir NY, Isikdogan A, Ozkan M, Demirag GG, Coskun HS, Karabulut B, Evrensel T, Ustaoglu MA, Ozdemir F, Turna H, Yavuzsen T, Aykan F, Sevinc A, Akbulut H, Yuce D, Hayran M, Kilickap S

Open source

DOI: 10.1186/s12885-020-06758-9
Published: 2020 Mar 30
Container: BMC cancer
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s12885-020-06758-9,
  title = {Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study.},
  author = {Yalcin S and Dane F and Oksuzoglu B and Ozdemir NY and Isikdogan A and Ozkan M and Demirag GG and Coskun HS and Karabulut B and Evrensel T and Ustaoglu MA and Ozdemir F and Turna H and Yavuzsen T and Aykan F and Sevinc A and Akbulut H and Yuce D and Hayran M and Kilickap S},
  year = {2020},
  journal = {BMC cancer},
  doi = {10.1186/s12885-020-06758-9},
  url = {https://doi.org/10.1186/s12885-020-06758-9}
}

RIS

TY  - JOUR
TI  - Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study.
AU  - Yalcin S
AU  - Dane F
AU  - Oksuzoglu B
AU  - Ozdemir NY
AU  - Isikdogan A
AU  - Ozkan M
AU  - Demirag GG
AU  - Coskun HS
AU  - Karabulut B
AU  - Evrensel T
AU  - Ustaoglu MA
AU  - Ozdemir F
AU  - Turna H
AU  - Yavuzsen T
AU  - Aykan F
AU  - Sevinc A
AU  - Akbulut H
AU  - Yuce D
AU  - Hayran M
AU  - Kilickap S
PY  - 2020
JO  - BMC cancer
DO  - 10.1186/s12885-020-06758-9
UR  - https://doi.org/10.1186/s12885-020-06758-9
ER  -

APA

S, Y., F, D., B, O., NY, O., A, I., M, O., GG, D., HS, C., B, K., T, E., MA, U., F, O., H, T., T, Y., F, A., A, S., H, A., D, Y., M, H., & S, K. (2020). Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study.. BMC cancer. https://doi.org/10.1186/s12885-020-06758-9

Source records

pubmed · retrieved 2026-09-27T11:13:51.449Z
europe-pmc · retrieved 2026-09-27T11:13:51.450Z
doaj · retrieved 2026-09-27T11:13:51.462Z